Small molecules for combating multidrug-resistant superbug Candida auris infections

Acta Pharm Sin B. 2022 Nov;12(11):4056-4074. doi: 10.1016/j.apsb.2022.08.001. Epub 2022 Aug 12.

Abstract

Candida auris is emerging as a major global threat to human health. C. auris infections are associated with high mortality due to intrinsic multi-drug resistance. Currently, therapeutic options for the treatment of C. auris infections are rather limited. We aim to provide a comprehensive review of current strategies, drug candidates, and lead compounds in the discovery and development of novel therapeutic agents against C. auris. The drug resistance profiles and mechanisms are briefly summarized. The structures and activities of clinical candidates, drug combinations, antifungal chemosensitizers, repositioned drugs, new targets, and new types of compounds will be illustrated in detail, and perspectives for guiding future research will be provided. We hope that this review will be helpful to prompting the drug development process to combat this fungal pathogen.

Keywords: Antifungal agents; Antifungal targets; Candida auris; Drug resistance; Virulence factors.

Publication types

  • Review